Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.

Publication

Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.

Journal Paper/Review - Jul 1, 2022

Hatemi Gülen, Mahr Alfred, Takeno Mitsuhiro, Kim Doyoung, Melikoğlu Melike, Cheng Sue, McCue Shannon, Paris Maria, Chen Mindy, Yazici Yusuf

Citation

Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. RMD Open 2022; 8

Type

Journal Paper/Review (English)

Journal

RMD Open 2022; 8

Publication Date

Jul 1, 2022

Issn Electronic

2056-5933

Brief description/objective

To assess apremilast's impact on patient quality of life (QoL) in active Behçet's syndrome and correlations between improvement in patients' QoL and efficacy measures in the phase 3 RELIEF study.